消癌平片辅助化疗治疗晚期子宫内膜癌  

The clinical study of Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma

作　　者：钟慧 刘敏[2] 刘利英 任晓红 党洁 渠淑云 张娟[3] 刘静[4] Zhong Hui;Liu Min;Liu Liying;Ren Xiaohong;Dang Jie;Qu Shuyun;Zhang Juan;Liu Jing(Department of Gynaecolog, Shaanxi Province Nuclear Industry 215, Xianyang 712000, China)

机构地区：[1]陕西省核工业215医院妇科,咸阳712000 [2]延安大学附属医院肿瘤科,716000 [3]延安大学附属医院产科,716000 [4]陕西省西安高新医院妇科,710000

出　　处：《国际中医中药杂志》2018年第12期1129-1133,共5页International Journal of Traditional Chinese Medicine

基　　金：陕西省教育厅自然科学研究项目(2013JK0782).

摘　　要：目的评价消癌平片辅助AP方案(培美曲塞+顺铂)治疗不可切除的晚期子宫内膜癌的疗效。方法将符合入选标准的268例晚期子宫内膜癌患者采用随机数字表法分为2组,每组134例。对照组采用AP化疗方案,观察组在对照组基础上加服消癌平片。2组均3周为1个化疗周期,共治疗4个周期,随访2年。采用化学发光法检测IgG、IgA及IgM,采用流式细胞仪检测CD3+及CD4+;采用Karnofsky功能状态评分(Kamofsky Performance Status, KPS)评价生活质量;观察治疗期间的毒副作用,以及随访期间患者生存率,总生存时间(overall survival, OS)、无疾病进展生存时间(progression-freely- survival, PFS),评价临床疗效。结果观察组临床有效率为64.2%(86/134)、疾病控制率为86.5%(116/134),对照组分别为52.2%(70/134)、76.9%(103/134),2组临床有效率与疾病控制率比较,差异有统计学意义(Z值分别为3.542、3.871,P值分别为0.041、0.039)。治疗后,观察组IgG、IgA、IgM、CD3+、CD4+水平均高于对照组(t值分别为4.725、4.930、4.259、4.571、4.006,P值均<0.01)。治疗后1、2、3、4个周期,观察组KPS评分均高于同期对照组(t值分别为3.124、3.452、3.612、3.712,P值均<0.05)。治疗期间,观察组恶心呕吐、腹痛腹泻、骨髓抑制、心脏毒性、肝肾毒性及神经毒性发生率均低于对照组(t值分别为3.781、3.925、4.021、4.192、4.401、3.823,P值均<0.05)。随访期间,观察组PFS,OS,以及1、2年生存率均高于对照组(t值分别为4.241、4.421、3.735、3.982,P值均<0.05)。结论消癌平片联合AP方案可提高晚期子宫内膜癌患者免疫力,降低化疗所致毒副作用,延长生存时间。ObjectiveTo observe the clinical study of Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma. MethodsA total of 268 patients with advance endometrial carcinoma in our hospital were divided into treatment group and control group, 134 cases in each group. The control group was treated by AP regimen and the treatment group was given Xiaoaiping tablet combined AP regimen. The treatment was 3 weeks per course, 4 periods performance, and the 2 year follow-up. After the treatment, the immune index, including IgG, IgA, IgM, CD3+ and CD4+ were detected by a chemical lighting method in the 2 groups. The KPS scores were observed to evaluate the life quality in the 2 groups. During the treatment, the adverse effects of chemotherapy in patients were observated during the treatment. And the survival rates, overall survival and progression-freely-survival were also observed. ResultsAfter the treatment, the control rate and efficiency rate were 86.5% (116/134) and 64.2% (86/134) in treatment group, while the control rate and efficiency rate were 76.9% (103/134) and 52.2% (70/134) in control group, where there were significantly difference in control rate and efficiency rate (Z values were 3.542 and 3.871, P values were 0.041 and 0.039). After the treatment, the levels of IgG, Ig A, IgM, CD3+ and CD4+ in treatment group were significantly higher than control group (t values were 4.725, 4.930, 4.259, 4.571 and 4.006, P<0.01). After the 1st-4th period of treatment, the KPS scores in treatment group were significantly higher than the control group (t values were 3.124, 3.452, 3.612 and 3.712, P<0.05). After the treatment, the PFS, OS, 1 year survival rate and 2 year survival rate were significantly lower in treatment group than control group (t values were 4.241, 4.421, 3.735 and 3.982, P<0.05). ConclusionsThe Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma has a good effect, could promote the immune function, decease the adverse e

关 键 词：癌 子宫内膜样 抗肿瘤联合化疗方案 消癌平片 药物相关副作用及不良反应 免疫 细胞 存活率 无病生存 生活质量 

分 类 号：R737.33[医药卫生—肿瘤]